. 2023 Nov 2;7(6):975–985. doi: 10.1007/s41669-023-00438-7

Table 3.

Scenario E: ICERs for RZV versus no vaccine for US IC adults, across ranges of values for starting age, IC status duration, and annual herpes zoster incidence

IC status duration (years)	Annual incidence of HZ (per 1000 person-years)^a, based on a starting age of 35 years
IC status duration (years)	10	20	40	60	80
1	US$548,377	US$312,732	US$146,083	US$82,966	US$51,646
2	US$300,961	US$133,185	US$33,046	Cost saving	Cost saving
3	US$199,578	US$70,612	Cost saving	Cost saving	Cost saving
4	US$143,150	US$38,106	Cost saving	Cost saving	Cost saving
5	US$104,716	US$17,323	Cost saving	Cost saving	Cost saving
30	Cost saving	Cost saving	Cost saving	Cost saving	Cost saving

	Annual incidence of HZ (per 1000 person-years)^a
		6	7	8	9	10
Starting age (years)	25
IC status duration (years)	15	US$66,285	US$47,555	US$33,256	US$21,985	US$12,878
IC status duration (years)	30	US$18,192	US$8549	US$480	Cost saving	Cost saving
Starting age	35
IC status duration	15	US$31,638	US$21,137	US$12,565	US$5,455	Cost saving
IC status duration	30	US$12,694	US$7989	US$1211	Cost saving	Cost saving
Starting age	45
IC status duration	15	US$12,828	US$13,225	US$7028	US$1569	Cost saving
IC status duration	30	US$3533	US$6251	US$3327	US$304	Cost saving

All ZONA IC Model input values other than those varied in this scenario were consistent with the base-case analysis for US HSCT adults (starting age 35 years)

HSCT hematopoietic stem cell transplantation, HZ herpes zoster, IC immunocompromised, ICER incremental cost-effectiveness ratio, RZV recombinant zoster vaccine, US United States, ZONA Zoster Economic Analysis

^aRZV efficacy and waning values were estimated based on the annual HZ incidence value considered. For more detail, please see the ‘Data Sources’ subsection in the manuscript, and electronic supplementary Figs. A3 and A4